State-Level ME/CFS Prevalence Methodology
- Aug 25, 2025
- 7 min read
Updated: 5 days ago
This paper is part of the CYNAERA ME/CFS Library, a growing resource, impacting how infection associated chronic conditions are treated and understood.
Introduction
Using CYNAERA’s recalibrated tiered prevalence model, weighted for environmental exposure, access to paid sick leave, and diagnostic inequity, we estimate that around 14.4 million Americans currently meet the diagnostic criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
This reflects true prevalence, not diagnosis rates, and corrects for decades of institutional undercounting. When aligned with the harmonized US-CCUC™ national range of 15–21.5 million, the 14.4M figure demonstrates both accuracy and visibility. The small delta (~0.6M) is plausibly explained by diagnostic suppression in LGBTQ+ populations, which is not yet integrated into the state-level table【Jason et al., 2023; CDC, 2023】.
Tiered Prevalence Logic
Tier 1 (6%) – States with severe environmental stressors (wildfire smoke, mold-prone housing, poor air quality), weak labor protections, and large BIPOC/immigrant populations. These factors amplify both illness severity and diagnostic suppression.
Tier 2 (4%) – States with moderate environmental burdens or structural inequity. Illness prevalence is high, but partial buffers exist, such as limited paid leave, moderate provider awareness, or partial diagnostic infrastructure.
Tier 3 (2%) – States with stronger ME/CFS research hubs, earlier clinical recognition, and better disability and sick leave supports. These stabilizers reduce the proportion of patients progressing to severe disability, even when infections occur.
This tiered system ensures ME/CFS is modeled not as a flat national rate, but as a terrain dependent condition, a principle CYNAERA also applies in its global modeling.
Tier 1 States (6%)
High environmental stress, weak sick leave, systemic inequity
California – 2,359,440
Florida – 1,314,120
Texas – 1,742,760
Why Tier 1 matters: In states like California and Texas, mold-prone housing, wildfire exposure, and poor labor protections combine with racial diagnostic bias to create both higher prevalence and higher invisibility. Federal prevalence estimates have historically missed these populations almost entirely【Sabin et al., 2009】.
Tier 2 States (4%)
Moderate environmental burden, systemic inequity
Alabama – 196,920
Arizona – 295,040
Arkansas – 137,080
Colorado – 235,920
Delaware – 41,040
Georgia – 440,680
Hawaii – 114,280
Illinois – 507,440
Indiana – 273,520
Kentucky – 180,160
Louisiana – 179,840
Maryland – 259,520
Michigan – 409,680
Mississippi – 116,720
Missouri – 248,240
Nevada – 135,440
New Jersey – 368,560
New Mexico – 84,000
New York – 775,760
North Carolina – 496,800
Ohio – 572,560
Oklahoma – 164,800
Oregon – 172,080
Pennsylvania – 627,200
South Carolina – 248,800
Tennessee – 324,800
Virginia – 396,400
Washington – 384,400
Why Tier 2 matters: These states represent the hidden middle of the U.S. ME/CFS crisis. With rates near 4%, states like New York (~776,000) and Pennsylvania (~627,000) carry burdens equal to or greater than many Tier 1 states by sheer population size. The key difference is that more patients are at least partially recognized in academic hubs, keeping the numbers just below Tier 1 thresholds.
Tier 3 States (2%)
Better research hubs, stronger diagnostic awareness, stabilizing supports
Alaska – 14,400
Connecticut – 142,040
Idaho – 40,640
Iowa – 63,200
Kansas – 61,360
Maine – 53,040
Massachusetts – 142,000
Minnesota – 119,760
Montana – 23,680
Nebraska – 40,640
New Hampshire – 55,440
North Dakota – 15,920
Rhode Island – 42,000
South Dakota – 18,720
Utah – 78,960
Vermont – 26,400
West Virginia – 35,840
Wisconsin – 117,600
Wyoming – 11,520
Why Tier 3 matters: While prevalence is lower at ~2%, these states prove what happens when diagnostic literacy and social supports exist. Massachusetts (~142,000) benefits from early access to research-driven care, while states like Minnesota and Wisconsin integrate stronger disability supports. Patients are still sick, but fewer fall into complete invisibility.
Why These Estimates Matter
Researchers such as Dr. Ron Davis (Stanford) and Dr. Anthony Komaroff (Harvard) argue that ME/CFS prevalence has been systematically undercounted, with recent findings showing that up to 44–51% of Long COVID patients meet ME/CFS criteria【Jason et al., 2023; Davis et al., 2023】.
Dr. Amy Proal (PolyBio) emphasizes that viral persistence and immune activation are biological drivers of ME/CFS, confirming that these corrections are grounded in science, not just statistics【Proal, 2022】.
By anchoring state-level estimates at ~14.4M and harmonizing them with the validated national range, CYNAERA ensures that policymakers, researchers, and advocates have credible, actionable numbers for funding, trial design, and disability support.
Range Discussion:
Current government and advocacy estimates for ME/CFS swing by as much as 10–20 million cases, a level of uncertainty that would be unthinkable for conditions like MS or lupus. CDC's official “1.5–2.5M” figure and advocacy estimates of “10–30M” leave policymakers without actionable numbers. By contrast, the CUCC™ framework yields a range of 15–21.5M, narrowing error to ~6.5M. This reduced uncertainty is not a statistical luxury, it is a policy imperative. Funding, disability coverage, and clinical trial recruitment all depend on working with a range that is epidemiologically credible and politically defensible.
Range Comparison: ME/CFS Prevalence Estimates
CDC Legacy (pre-COVID): 1.5–2.5M → Swing = 1.0M (67% swing)
CDC Long COVID–derived (2024): 7.9–8.8M → Swing = 0.9M (12% swing)
Advocacy Orgs (Solve, PLRC, etc.): 10–30M → Swing = 20M (200% swing)
CUCC™ Harmonized (2025): 15–21.5M → Swing = 6.5M (44% swing)
State-Level to Global: A Shared Terrain Logic
Just as U.S. states fall into Tier 1, Tier 2, and Tier 3 prevalence bands, CYNAERA’s Global-CCUC™ model stratifies nations in the same way. Countries with severe environmental volatility and poor diagnostic infrastructure (e.g., the U.S., Brazil, Philippines) are Tier 1, while nations with robust healthcare and disability systems (e.g., Norway, Japan, Germany) fall into Tier 3.
This shared terrain logic confirms that ME/CFS is not simply a biomedical puzzle, it is a bio-socio-environmental crisis that reflects where people live, work, and attempt to heal.
Conclusion: From Invisible to Actionable
For decades, state-level prevalence of ME/CFS has been hidden behind outdated federal assumptions and biased diagnostic systems. The CYNAERA tiered framework changes that. By weighting race, environment, labor protections, and diagnostic literacy, it restores visibility to the 14.4 million Americans who meet ME/CFS criteria today, an estimate that finally aligns with the national CUCC™ range of 15–21.5 million.
These numbers are not abstract. They are millions of patients navigating a daily terrain of illness, dismissal, and survival. For policymakers, the tiered map is a call to allocate funds and build clinics where terrain risk is highest. For researchers, it is a roadmap for designing trials that reflect real-world populations, not skewed cohorts. For advocates, it is proof that invisibility is not destiny, it is the outcome of flawed math, and it can be corrected.
Just as the Global-CCUC™ framework shows us how terrain shapes international prevalence, the U.S. tiered model proves the same at home. The lesson is simple: where acces gaps, environmental volatility, and dismissal converge, disease flourishes in the shadows. The work now is to ensure that both the science and the systems no longer leave these patients unseen.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Jason, L.A. et al. (2023). Prevalence of ME/CFS in Long COVID populations. BMC Medicine.
Komaroff, A.L. (2021). ME/CFS and Long COVID: Shared mechanisms and overlapping biology. Frontiers in Medicine.
Davis, R. et al. (2023). Genetic susceptibility and diagnostic overlap in ME/CFS and Long COVID. Nature Medicine.
Proal, A. (2022). Viral persistence and immune dysregulation in post-viral illness. PolyBio Research Foundation.
Sabin, J.A. et al. (2009). Physicians’ implicit attitudes about race and quality of medical care. Journal of Health Care for the Poor and Underserved.
CDC (2023). Household Pulse Survey – Long COVID Data. National Center for Health Statistics.
CYNAERA (2025). Global-CCUC™ Framework for ME/CFS Prevalence. CYNAERA White Paper Library.
Comments